Nature Aging：厦门大学张杰团队揭示阿尔茨海默病新靶点——CDK3

Core Viewpoint - The research identifies CDK3 as a key driver of neuronal death and brain atrophy in Alzheimer's disease, providing a new target for therapeutic intervention and a relevant mouse model for studying the disease [2][5][6]. Group 1: Research Findings - CDK3 levels are elevated in the brains of Alzheimer's patients and correlate with disease severity [5]. - The study developed two mouse models that restore CDK3 activity, leading to significant neuronal death, hippocampal atrophy, and cognitive deficits [5]. - Single-cell RNA sequencing revealed that neurons activated cell cycle and various cell death pathways, indicating that re-entry into the cell cycle leads to cell death [5]. Group 2: Therapeutic Implications - The research team identified BMX330, a small molecule inhibitor that specifically targets CDK3, which significantly reduced neuronal death and hippocampal atrophy in the mouse models [6]. - BMX330 also improved cognitive function, positioning CDK3 as a potential therapeutic target for Alzheimer's disease [6].